CONTROL BIONICS LIMITED — Board/Management Information 2025

Mar 25, 2025

==> picture [145 x 45] intentionally omitted <==

26 March 2025

ASX ANNOUNCEMENT (ASX:CBL)

BOARD UPDATE: APPOINTMENT OF DR STEPHANIE PHILLIPS AND RESIGNATION OF FOUNDER, PETER FORD

Control Bionics Limited (ASX:CBL) announces the appointment of Dr Stephanie Phillips to its Board of Directors, effective immediately. Dr Phillips brings with her over three decades of clinical, academic and leadership experience in anaesthesia and critical care, and is a highly respected figure in the Australian medical community.

Dr Phillips (BMed, FRCA, FANZCA, GAICD) is a Consultant Anaesthetist and Clinical Associate Professor at the Australian National University. She has formerly held senior leadership positions at the University of Sydney including Deputy Head of School, and Academic Lead for Education at the Sydney Adventist Hospital Clinical School and was a member of the Academic Boards of both the University and of the Faculty of Medicine. She has been Managing Director of Northern Specialist Anaesthetics Pty Ltd. She was also the Inaugural Chair of the Australian Society of Anaesthetists Science, Prizes, Awards, and Research Committee. Her international training and clinical expertise span paediatric, cardiothoracic and neurosurgical anaesthesia. Her more recent research interests focus on neuromuscular function monitoring during anaesthesia.

A veteran of over 10 international medical aid missions, Dr Phillips is deeply committed to improving patient outcomes and reducing anaesthesia-related morbidity. Her strong research background, medical insight and leadership experience will add significant value to Control Bionics as it expands into new markets across assistive communication, rehabilitation and health diagnostics.

Resignation of Founder, Peter Ford

The Board also announces the resignation of Peter Ford, founder of Control Bionics, from the Board from 31 March 2025. Peter’s vision and passion were the driving force behind the creation of Control Bionics. Inspired by a desire to help unlock the potential of brilliant minds like Stephen Hawking, Peter’s insight in 1999—that damaged muscles still emit usable electrical signals—led to the development of the NeuroNode and the founding of the Company.

Under Peter’s guidance, Control Bionics has grown from a visionary idea into a publicly listed company helping people around the world regain their voice and mobility. His legacy is embedded in the DNA of the company, and his impact on the assistive technology sector is profound.

While Peter is stepping down from the Board, he remains passionately committed to the success of Control Bionics and continues to be a significant shareholder.

Chairman Samuel Straface Ph D. said:

“On behalf of the entire Board, I would like to sincerely thank Peter for his extraordinary contribution to Control Bionics over the past 25 years. His innovation, leadership and unwavering belief in the power of technology to change lives has left an indelible mark on the Company. We are delighted that Peter will remain a close part of the Control Bionics family as a major shareholder.”

“We are equally pleased to welcome Dr Stephanie Phillips to the Board. Her extensive clinical experience, academic leadership and strong track record in improving health outcomes are highly aligned with our mission. We look forward to her contribution as we continue to grow and diversify the business.”

This announcement has been authorised for release by the Board of Control Bionics Limited.

For further information, please contact:

Jeremy Steele CEO & Managing Director jsteele@controlbionics.com

Brett Crowley

Company Secretary brettcrowley@controlbionics.com

Investor Relations:

Joe Durak Executive Director & Founder Lynx Advisors joe@lynxadvisors.com.au +61 414 465 582

About Control Bionics:

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. DROVE allows powered users the independence to operate their wheelchairs in their own homes for the first time. DROVE recently got approved by the TGA as a Class I medical device.

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip ® . This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics has a 20% investment in Neuro Elite Athletics to drive rapid growth of their NeuroBounce program in the US and Australia.

Control Bionics operates in North America, Australia, Singapore and Japan.

For further information visit the website: https://www.controlbionics.com/